Price (delayed)
$15
Market cap
$2.2B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
$2.17B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
There are no recent dividends present for TGTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.